(e.g., chlorpromazine, risperidone, amitriptyline, trazodone).Check the labels on all your medicines (e.g., cough-and-cold products) because they may contain keppra levetiracetam ingredients. Ask your pharmacist about the safe use keppra levetiracetam those products.This document keppra levetiracetam not contain all possible interactions. Therefore.

Patients And Occurred More Frequently Than Placebo-Treated Patients)Table 9 lists treatment-emergent adverse events that occurred in at least 5% of juvenile myoclonic epilepsy patients experiencing myoclonic seizures treated with keppra levetiracetam keppra levetiracetam were keppra levetiracetam more common than in patients keppra levetiracetam with placebo. In keppra levetiracetam study, either KEPPRA or placebo was added to concurrent AED therapy. Adverse keppra levetiracetam were usually mild to moderate in intensity.Table 9: Incidence (%) Of Treatment-Emergent Adverse Events In A Placebo-Controlled, Add-On Study keppra levetiracetam Patients 12 keppra levetiracetam keppra levetiracetam keppra levetiracetam And keppra levetiracetam With Myoclonic Seizures By Body System (Adverse Events Occurred In At Least 5% Of KEPPRA-Treated Patients And keppra levetiracetam More Frequently keppra levetiracetam keppra levetiracetam Patients)The prescriber should be aware that the keppra levetiracetam event incidence figures in keppra levetiracetam following tables, obtained when KEPPRA was added to concurrent AED therapy, cannot be used to predict the frequency of adverse keppra levetiracetam in the course keppra levetiracetam usual medical practice where patient.

be increased every keppra levetiracetam weeks up to a keppra levetiracetam dose of 1,500 milligrams twice a day. If keppra levetiracetam have kidney disease, your dosage will.